NSU Newsroom
SharkBytes
Horizons
This version of NSU News has been archived as of February 28, 2019. To search through archived articles, visit nova.edu/search. To access the new version of NSU News, visit news.nova.edu.
This version of SharkBytes has been archived as of February 28, 2019. To search through archived articles, visit nova.edu/search. To access the new version of SharkBytes, visit sharkbytes.nova.edu.
NSU Research Spotlight: Researchers Find Brain Levels of Vitamin B12 Decrease with Age; Much lower in those with Autism and Schizophrenia
Richard Deth, Ph.D.
A new study published in the online journal, Public Library of Science One (PLOS One) found that Vitamin B12 levels in the brain are significantly decreased in the elderly and are much lower in individuals with autism or schizophrenia, as compared to their peers at similar ages. For example, children with autism under the age of 10 were found to have three times lower brain B12 levels, which is similar to levels for generally healthy adults in their 50s, indicating a premature decrease.
The international research team led by Richard Deth, Ph.D., professor of pharmacology at Nova Southeastern University’s (NSU) College of Pharmacy, analyzed tissue from otherwise healthy deceased donors along with tissue from donors who had autism or schizophrenia to make the comparisons.
“These are particularly significant findings because the differences we found in brain B12 with aging, autism and schizophrenia are not seen in the blood, which is where B12 levels are usually measured.” said Mr. Deth. “The large deficits of brain B12 from individuals with autism and schizophrenia could help explain why patients suffering from these disorders experience neurological and neuropsychiatric symptoms.”
The study also found healthy elderly people in the age range of 61-80 have about three times lower levels of total brain B12 than younger age groups, which is a result of normal aging. This normal decrease may help adjust brain metabolism to sustain its function across the lifespan.
An active form of B12 called methylcobalamin, or methyl B12, supports normal brain development by its control through a process known as epigenetic regulation of gene expression. Remarkably, the brain level of methyl B12 was found to be more than 10 times lower in healthy elderly people than in healthy younger people. A lower than normal level of methyl B12 in the brain could adversely affect neurodevelopment in younger years and could disrupt learning and memory later in life.
Both autism and schizophrenia are associated with oxidative stress, which also plays an important role in aging, and oxidative stress may underlie the decreased brain B12 levels observed in this study. The findings suggest the need for further research to determine if the use of supplemental methyl B12 and antioxidants like glutathione could help prevent oxidative stress and be useful in treating these conditions.
The research team consisted of Richard Deth, Ph.D; Yiting Zhang (Northeastern University); Nathaniel Hodgson (Harvard University); Malav S. Trivedi (Nova Southeastern University); Hamid Abdolmaleky (Boston University); and Margot Fournier, Michel Cuenod and Kim Quang Do (Lausanne University, Switzerland).
Their findings are published in the peer-reviewed journal, PLOS1 in an article titled “Decreased brain levels of vitamin B12 in aging, autism and schizophrenia.” Read the full article at: http://dx.plos.org/10.1371/journal.pone.0146797
Research reported in this press release was supported by the Autism Research Institute.